PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Tilray Brands, Inc. (TLRY.TO)
2.000.05 (2.56%)
1.90 - 2.15
0.48 - 2.54
9.88M / 3.06M (Avg.)
-0.59 | -3.40
Gauges a company's financial stability and solvency. Value investors pay close attention to leverage and liquidity risk, ensuring the company has enough cushion to withstand downturns without impairing shareholder value.
0.17
D/E ratio near Drug Manufacturers - Specialty & Generic median of 0.17. Philip Fisher would examine if industry-standard leverage is optimal for the business model.
-48.30
Net cash position versus Drug Manufacturers - Specialty & Generic median net debt of 1.19. Peter Lynch would praise the flexibility but check if overcapitalized versus growth opportunities.
-3.49
Negative coverage while Drug Manufacturers - Specialty & Generic median is 0.00. Seth Klarman would scrutinize operating performance and look for turnaround catalysts.
1.54
Current ratio 50-75% of Drug Manufacturers - Specialty & Generic median of 2.12. Martin Whitman would look for hidden assets or working capital optimization.
67.63%
Intangibles exceeding 1.5x Drug Manufacturers - Specialty & Generic median of 10.67%. Michael Burry would check for aggressive accounting and hidden risks.